Physician profile

Leroy Gurganious

Orthopaedic Surgery · Fayetteville, TN

NPI 1710097290

$213.71

in general payments reported to CMS, 2019-2025

9 companies · none reported in 2025

Payments by year

General payments by program year, as reported to CMS.

What the payments were for

Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.

View as a table
Payment typeAmount (2023-2025)
Food and Beverage$40.16

Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.

Who reported paying

General payments only, as reported to CMS. Product names cover 2023-2025.

CompanyGeneral paymentsYearsTop products
Stryker Corporation $44.99 2022
Boston Scientific Corporation $40.16 2024 Wavewriter Alpha Prime 16
Conformis, INC. $34.47 2020
Triad Life Sciences INC. $18.33 2022
Pacira Therapeutics, INC. $16.89 2020
Smith+Nephew, INC. $16.72 2022
Paragon 28, INC. $15.16 2020
Bioventus LLC $14.95 2020
Endo Pharmaceuticals INC. $12.04 2020

Drugs and devices associated with these payments

CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.

If you want to bring it up

Most clinicians are glad to talk about this. A respectful way in:

These are normal questions. A good clinician will welcome them.

Share this page

Payment summary

Leroy Gurganious

$213.71

in general payments reported 2019-2025

Years
2020-2024
Top company
Stryker Corporation

https://glasscript.com/doctor/554190/leroy-gurganious

Source: CMS Open Payments, program years 2019-2025. Payments are legal and often routine.

Keep an eye on this page

Get an email when the next June refresh changes this page. No account needed.

Watch this doctor

Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.